Trial · NCT02943733
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
NCT02943733, Phase 1, Terminated, University of Wisconsin, Madison
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs. Trials, record NCT02943733. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02943733
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
- NCT number
- NCT02943733
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
- Interventions
- TAS-102, Temozolomide, Filgrastim, Pegfilgrastim
- First posted
- 2016-10-25
- Last updated
- 2022-09-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Maximum Tolerated Dose (MTD) of TAS-102 | Up to 2 years | Investigate the safety and determine the MTD of TAS-102 administered in combination with TMZ in patients with advanced NETs. Treatments will continue to disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST). |
| Primary | Part 2: Overall Response Rate | Up to 5 years | Response rate defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR), assessed as per RECIST criteria. Assessments performed using RECIST criteria. |
| Secondary | Part 2: Progression Free Survival (PFS) | Up to 5 years | Defined as the time from the start of treatment to the date of first documented progression or any cause of death during the study, assessed according to RECIST. Analyzed using the Kaplan-Meier method. |
| Secondary | Part 2: Overall Survival | Up to 5 years | Defined as the time from the start of treatment to the date of expiration. Analyzed using the Kaplan-Meier method. |
| Secondary | Part 2: Disease Control Rate | Up to 5 years | Defined as the percentage of patients who achieved complete response, partial response, and stable disease by investigator assessment as per RECIST. |
| Secondary | Part 2: Duration of Response | Up to 5 years | Analyzed using the Kaplan-Meier method. |
| Secondary | Part 2: Safety and Tolerability, Assessed per RECIST Criteria | Up to 5 years | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
| Secondary | Part 2: Biochemical Response defined as normalization or >50% reduction in levels of Chromogranin A | Up to 5 years | A major biochemical response will be defined as normalization or \>50% reduction in levels of Chromogranin A. Chromogranin A is elevated in up to 60% of functioning and nonfunctioning pancreatic endocrine tumors. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02943733
GET https://conductscience.org/api/trials/v1/NCT02943733/registered